NaHS-treated mice exhibited a reduced body weight gain ratio, serum triglyceride, blood glucose, and serum insulin, thereby suggesting that the NaHS treatment manner in this study may also act as a beneficial function in the context of obesity and type 2 diabetes. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.